Serum Institute's second COVID vaccine likely to be launched in September

Updated : March 27, 2021 04:14 PM IST

He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 percent.

"Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.

Covovax is the protein-based COVID-19 vaccine developed by Novavax, headquartered in the US.

Serum Institute of India, the world's biggest Covid-19 vaccine maker, is hopeful to launch Covovax by September this year, CEO Adar Poonawalla announced on Saturday.

"Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India," said Adar Poonawalla.

He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 percent. "Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.

Covovax is the protein-based COVID-19 vaccine developed by Novavax, headquartered in the US.

In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.

Published : March 27, 2021 04:13 PM IST

Serum Institute's second COVID vaccine likely to be launched in September

You May Also Like

Australia urges AstraZeneca to send 1 million COVID-19 vaccine doses to PNG after EU clearance

IndiGrid to raise up to Rs 1,000 crore via NCDs

As govt liberalises vaccine sales, Karnataka to purchase 1 crore doses of Covishield

Trending on CNBC-TV18

recommended for you